ISOLATION OF TARGETS FOR ANTIFUNGAL DRUGS IN C. ALBICANS
白色念珠菌中抗真菌药物靶标的分离
基本信息
- 批准号:6071445
- 负责人:
- 金额:$ 18.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-09-30 至 2002-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Candida albicans is an important human pathogen that is the leading cause of invasive fungal disease in surgical patients, infants, diabetics and immunocomprimised individuals. Despite treatment with cytostatic drugs, the rate of mortality from systemic Candida infections approaches 30%. A major impediment to the development of new drugs is the difficulty of identifying suitable targets for drug design. The biology of Candida precludes the use of a classical genetic approach to identify target genes. In this phase application, we propose to apply novel approaches to inhibit gene function in Candida. First, we will apply an approach that we have employed successfully in mammalian cells: to inhibit the function of genes by the expression of antisense RNA. We also propose to assess the utility of a newly emerging method for creating loss-of-function phenotypes: the expression of double-stranded RNA. The goal of this phase I application is to demonstrate the feasibility of performing genetic screens in Candida by ablating gene function with antisense RNA or with double-stranded RNA. PROPOSED COMMERCIAL APPLICATION: The ability to identify suitable targets for drug design in Candida albicans will yield two potential avenues for commercialization. First, the targets can be deployed as drug-discovery candidates with the help of corporate partners. Second, the technical approaches described herein may be applied in collaboration with one or more corporate partners.
白色念珠菌是一种重要的人类病原体,是外科手术患者、婴儿、糖尿病患者和免疫缺陷个体中侵袭性真菌疾病的主要原因。尽管使用细胞抑制药物治疗,系统性念珠菌感染的死亡率仍接近30%。新药开发的一个主要障碍是难以确定药物设计的合适靶点。念珠菌的生物学排除了使用经典的遗传学方法来鉴定靶基因。在这一阶段的应用中,我们建议应用新的方法来抑制念珠菌的基因功能。首先,我们将应用我们在哺乳动物细胞中成功使用的方法:通过表达反义RNA来抑制基因的功能。我们还建议评估一种新出现的方法用于创建功能丧失表型的实用性:双链RNA的表达。该I期申请的目的是证明通过用反义RNA或双链RNA消除基因功能在念珠菌中进行遗传筛选的可行性。拟定商业应用:在白色念珠菌中鉴定药物设计的合适靶点的能力将产生两种潜在的商业化途径。首先,这些目标可以在企业合作伙伴的帮助下作为药物发现候选人部署。第二,本文描述的技术方法可以与一个或多个公司合作伙伴协作应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID H. BEACH其他文献
DAVID H. BEACH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID H. BEACH', 18)}}的其他基金
EX-VIVO EXPANSION OF HUMAN PANCREATIC EPITHELIAL CELLS
人胰腺上皮细胞的离体扩增
- 批准号:
6071707 - 财政年份:2000
- 资助金额:
$ 18.4万 - 项目类别:
IMPROVED VECTORS FOR THERAPEUTIC PROTEIN PRODUCTION
用于治疗性蛋白质生产的改进载体
- 批准号:
6390067 - 财政年份:2000
- 资助金额:
$ 18.4万 - 项目类别:
IMPROVED VECTORS FOR THERAPEUTIC PROTEIN PRODUCTION
用于治疗性蛋白质生产的改进载体
- 批准号:
6074340 - 财政年份:2000
- 资助金额:
$ 18.4万 - 项目类别:
EARLY DIAGNOSIS OF CANCER: THE CANFIND CONSORTIUM
癌症早期诊断:CANFIND 联盟
- 批准号:
6175299 - 财政年份:1999
- 资助金额:
$ 18.4万 - 项目类别:
EARLY DIAGNOSIS OF CANCER: THE CANFIND CONSORTIUM
癌症早期诊断:CANFIND 联盟
- 批准号:
6377764 - 财政年份:1999
- 资助金额:
$ 18.4万 - 项目类别:
TECHNOLOGIES FOR GENETIC MANIPULATION OF TUMOR CELLS
肿瘤细胞基因操控技术
- 批准号:
6015590 - 财政年份:1999
- 资助金额:
$ 18.4万 - 项目类别:
EARLY DIAGNOSIS OF CANCER: THE CANFIND CONSORTIUM
癌症早期诊断:CANFIND 联盟
- 批准号:
6074244 - 财政年份:1999
- 资助金额:
$ 18.4万 - 项目类别:
A SYSTEMATIC APPROACH TO EARLY DIAGNOSIS OF CANCER
癌症早期诊断的系统方法
- 批准号:
6021536 - 财政年份:1999
- 资助金额:
$ 18.4万 - 项目类别:
EARLY DIAGNOSIS OF CANCER: THE CANFIND CONSORTIUM
癌症早期诊断:CANFIND 联盟
- 批准号:
6522553 - 财政年份:1999
- 资助金额:
$ 18.4万 - 项目类别:
相似海外基金
Extending the utility and durability of antifungal agents via innovative treatment regimens that minimise drug resistance
通过创新治疗方案最大限度地减少耐药性,延长抗真菌药物的效用和持久性
- 批准号:
MR/Y002164/1 - 财政年份:2024
- 资助金额:
$ 18.4万 - 项目类别:
Research Grant
Engineering microbial cell factories for production of improved polyene antifungal agents
工程微生物细胞工厂用于生产改进的多烯抗真菌剂
- 批准号:
2898887 - 财政年份:2023
- 资助金额:
$ 18.4万 - 项目类别:
Studentship
Morphological profiling for the development of antifungal agents
用于开发抗真菌药物的形态分析
- 批准号:
22H02216 - 财政年份:2022
- 资助金额:
$ 18.4万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
An efficient approach to find therapeutically effective antifungal agents
寻找治疗有效的抗真菌药物的有效方法
- 批准号:
22K05337 - 财政年份:2022
- 资助金额:
$ 18.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating light-activated therapeutic compounds as antifungal agents.
研究光激活治疗化合物作为抗真菌剂。
- 批准号:
2753345 - 财政年份:2022
- 资助金额:
$ 18.4万 - 项目类别:
Studentship
Discovery of novel therapeutic agents for biliary tract and pancreatic cancer based on antifungal agents
基于抗真菌药物的胆道癌和胰腺癌新型治疗药物的发现
- 批准号:
20H03533 - 财政年份:2020
- 资助金额:
$ 18.4万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of antifungal agents that target essential protein kinases in A. fumigatus.
开发针对烟曲霉必需蛋白激酶的抗真菌剂。
- 批准号:
2456629 - 财政年份:2020
- 资助金额:
$ 18.4万 - 项目类别:
Studentship
Elucidation of tip growth factor of fungi and construction of screeing system for antifungal agents
真菌尖端生长因子的阐明及抗真菌药物筛选体系的构建
- 批准号:
19K05738 - 财政年份:2019
- 资助金额:
$ 18.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Ambruticins: An inspiration to develop novel biocatalysts and antifungal agents
Ambruticins:开发新型生物催化剂和抗真菌剂的灵感
- 批准号:
2107517 - 财政年份:2018
- 资助金额:
$ 18.4万 - 项目类别:
Studentship